Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,350 signal articles · 72 in last 24h · 115,788 total before filter · latest 57m ago
72last 24h
1744last 7d
294● bullish (7d)
170● bearish (7d)
205publishers
AllMacro312Earnings814M&A103Regulatory25Product16Analyst25
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Why Adidas shares slumped following World Cup bump
Reuters Videos17d agobearishVIDEO
Why Adidas shares slumped following World Cup bump

<body><p>STORY: :: Was sponsoring the World Cup worth it?</p><p>:: Peter Devlin, Business reporter</p><p>"Was sponsoring the World Cup worth it?</p><p>If you ask Adidas - maybe not. Shares in the sportswear giant just suffered their biggest drop on record.</p><p>Its huge World Cup marketing bet delivered blockbuster sales - but profits couldn’t keep up.</p><p>Adidas went all in on football’s biggest stage - launching merchandise months before rivals Nike and Puma.</p><p>Then backed it all with a star-studded campaign featuring Timothée Chalamet, Lionel Messi and Bad Bunny.</p><p>And the campaign worked. Adidas sold four times more jerseys and twice as many footballs as the previous tournament, generating around €1.5 billion in World Cup-related sales.</p><p>But attention doesn’t come cheap. Adidas spent an extra €212 million on marketing. So was it worth it?</p><p>Adidas is racing to find its next hit as demand for its Samba and Gazelle sneakers cools.</p><p>But while trends fade, owning the world’s biggest sporting stage is something no rival can take away.</p><p>And in the battle for attention, that might just be the winning goal."</p></body>

🔎 Under the Radar: Teladoc Shares Tumble on Therapist Shortage
The Wall Street Journal17d agobearish
🔎 Under the Radar: Teladoc Shares Tumble on Therapist Shortage

Shares of Teladoc Health fell more than 25% Thursday after the telehealth company missed second-quarter revenue expectations and cut its full-year sales forecast. The pain is concentrated in BetterHelp, Teladoc's therapy and psychiatry platform, where revenue fell 12% to $212.6 million. Teladoc has pushed BetterHelp users toward insurance-covered therapy instead of cash-pay sessions.

Jersey Mike’s Is Taking Orders on Wall Street
The Wall Street Journal17d agobearish
Jersey Mike’s Is Taking Orders on Wall Street

Jersey Mike's has gone public. Shares of the sub giant are due to start trading today on the New York Stock Exchange after about 43.5 million shares priced at $23 each yesterday. The company raised about $1 billion in its IPO.

UiPath (PATH) Stock Could Be Below Fair Value On Its 80% Slump
Simply Wall St.17d agobearish
UiPath (PATH) Stock Could Be Below Fair Value On Its 80% Slump

UiPath stock is coming off a difficult five year stretch, with shareholders seeing the share price fall about 79.7%. However, current valuation checks now suggest the stock may be trading below its intrinsic value based on a Discounted Cash Flow (DCF) estimate. Over the past five years, UiPath has delivered a share price decline of 79.7%, which puts long term holders well under water and makes today’s pricing especially important for new and existing investors. UiPath’s ability to convert...

Qualcomm shares slip as profit outlook falls short of expectations
Proactive17d agobearish
Qualcomm shares slip as profit outlook falls short of expectations

Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) shares fell about 3% on Thursday after the chipmaker reported third quarter earnings that narrowly missed expectations and issued a weaker-than-expected profit outlook for the upcoming quarter. For the fiscal third quarter ended June 28, Qualcomm reported...

Missiles Are Hot. That’s Good for Lockheed Martin Stock.
Barrons.com17d agobearish
Missiles Are Hot. That’s Good for Lockheed Martin Stock.

The U.S. has fired a lot of missiles lately, leaving the Defense Department motivated to quickly replace and grow its missile stocks. “When you add the $54 billion dollars in this contract modification, you’re pushing $300 billion dollars of backlog for the company,” said CEO Jim Taiclet on Fox Business. Lockheed is tripling production of its PAC-3 missiles.